{'fraction_non_alphanumeric': 0.023370233702337023, 'fraction_numerical': 0.007380073800738007, 'mean_word_length': 5.409448818897638, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Overexpression of PCDH7 and SET Leads to Aberrant ERK and AKT Signaling and Promotes Prostate Cancer Progression

PI3K/AKT and RAF/MEK/ERK signaling pathways play an important role in cell survival and treatment resistance to facilitate prostate cancer (PCa) progression to castration resistant prostate cancer (CRPC). Most of PCa deaths are a result of distant metastasis. PCDH7, a cadherin superfamily transmembrane protein, is involved in cell‐cell recognition and adhesion. Recent reports suggest overexpression of PCDH7 promotes metastasis in lung and breast cancer and PCDH7 was shown to interact with SET in lung cancer. Overexpression of SET promoted cell proliferation, survival, drug resistance, invasion and metastasis in different cancers. We evaluated expression and function of PCDH7 and SET in PCa.